hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-10. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Berkelium(IV) fluoride (BkF4) is a yellow-green ionic solid and is isotypic with uranium tetrafluoride or zirconium tetrafluoride. Berkelium(III) fluoride (BkF3) is also a yellow-green solid, but it has two crystalline structures. The most stable phase at low temperatures is isotypic with yttrium(III) fluoride, while upon heating to between 350 and 600 °C, it transforms to the structure found in lanthanum trifluoride. Visible amounts of berkelium(III) chloride (BkCl3) were first isolated and characterized in 1962, and weighed only 3 billionths of a gram. It can be prepared by introducing hydrogen chloride vapors into an evacuated quartz tube containing berkelium oxide at a temperature about 500 °C. This green solid has a melting point of 600 °C, and is isotypic with uranium(III) chloride. Upon heating to nearly melting point, BkCl3 converts into an orthorhombic phase. Two forms of berkelium(III) bromide are known: one with berkelium having coordination 6, and one with coordination 8. The latter is less stable and transforms to the former phase upon heating to about 350 °C. An important property of radioactive solids has been studied on these two crystal forms: the structure of fresh and aged 249BkBr3 samples was probed by X-ray diffraction over a period longer than 3 years, so that various fractions of berkelium-249 had beta decayed to californium-249. No change in structure was observed upon the 249BkBr3—249CfBr3 transformation. However, other differences were noted for 249BkBr3 and 249CfBr3.
== History == Dalbavancin has undergone a phase-III clinical trial for adults with complicated skin infections, but in December 2007, the US Food and Drug Administration (FDA) said more data were needed before approval. Pfizer withdrew its marketing applications to conduct another phase-III clinical trial in September 2008. Durata Therapeutics acquired the rights to dalbavancin in December 2009, and has initiated two new phase-III clinical trials for treatment of ABSSSIs. Preliminary results in 2012 were promising. About 1,289 adults with ABSSSI were given dalbavancin or vancomycin randomly, and dalbavancin was found to exhibit efficacy comparable to vancomycin. In May 2014, dalbavancin was approved for medical use in the United States for ABSSSIs, including MRSA and Streptococcus pyogenes infections.
== In fiction == The creation of a mirror-image human is the basis of the 1950 short story "Technical Error" by Arthur C. Clarke. In this story, a physical accident transforms a person into his mirror image, speculatively explained by travel through a fourth physical dimension. H. G. Wells' The Plattner Story (1896) is based on a similar idea. In the 1970 Star Trek novel Spock Must Die! by James Blish, the science officer of the USS Enterprise is replicated in mirror-image form by a transporter mishap. He locks himself in the sick bay where he is able to synthesize mirror-image forms of basic nutrients needed for his survival. An alien machine that reverses chirality, and a blood-symbiont that functions properly only when in one chirality, were central to Roger Zelazny's 1976 novel Doorways in the Sand. On the titular planet of Sheri S. Tepper's 1989 novel Grass, some lifeforms have evolved to use the right-handed isomer of alanine. In the Mass Effect series, chirality of amino acids in foodstuffs is discussed often in both dialogue and encyclopedia files. In the 2014 science fiction novel Cibola Burn by James S. A. Corey, the planet Ilus has indigenous life with partially-mirrored chirality. This renders human colonists unable to digest native flora and fauna, and greatly complicates conventional farming. Consequently, the colonists have to rely upon hydroponic farming and food importation. In the 2017 Daniel Suarez novel Change Agent, an antagonist, Otto, nicknamed the "Mirror Man", is revealed to be a genetically engineered mirror-image human.
Ethylenediaminetetraacetic acid (EDTA), also called EDTA acid, is an aminopolycarboxylic acid with the formula [CH2N(CH2CO2H)2]2. This white, slightly water-soluble solid is widely used to bind to iron (Fe2+/Fe3+) and calcium ions (Ca2+), forming water-soluble complexes even at neutral pH. It is thus used to dissolve Fe- and Ca-containing scale as well as to deliver iron ions under conditions where its oxides are insoluble. EDTA is available as several salts, notably disodium EDTA, sodium calcium edetate, and tetrasodium EDTA, but these all function similarly.
Sources: en.wikipedia.org
Next to occupy the Oval Office, Reagan protégé and former VP George H. W. Bush (1989–93) maintained the hard line drawn by his predecessor and former boss. In his first prime time address to the nation, Bush held up a plastic bag of crack "seized a few days ago in a park across the street from the White House" (it was later revealed that DEA agents had to lure the seller to Lafayette Park to make the requested arrest). The administration increased narcotics regulation in the first National Drug Control Strategy, issued by the Office of National Drug Control Policy (ONDCP) in 1989. The director of ONDCP became commonly known as the US drug czar. In the National Defense Authorization Act for 1990–91, Congress included Section 1208 – the 1208 Program, expanded into the 1033 Program in 1996 – authorizing the Department of Defense to transfer surplus military equipment that the DoD determined to be "suitable for use in counter-drug activities", to local law enforcement agencies. As president, Bill Clinton (1993–2001), seeking to reposition the Democratic Party as tough on crime, dramatically raised the stakes for drug felonies with his signing of the Violent Crime Control and Law Enforcement Act of 1994. The act introduced the federal "three-strikes" provision that mandated life imprisonment for violent offenders with two prior convictions for violent crimes or drugs, and provided billions of dollars in funding for states to expand their prison systems and increase law enforcement.
Pepscan is a procedure for mapping and characterizing epitopes involving the synthesis of overlapping peptides and analysis of the peptides in enzyme-linked immunosorbent assays (ELISAs). The method is based on combinatorial chemistry and was pioneered by Mario Geysen and coworkers. Rob Meloen was one of Geysen's co-workers. He also played an important role in the development of numerous other new technologies, including vaccine and diagnostic product development for several viral diseases. From 1994 to 2010, Meloen was Professor of Special Appointment (Chair: Biomolecular Recognition) at Utrecht University. He was one of the co-founders of the company Pepscan (Lelystad, the Netherlands) and became Scientific Director (CSO). Pepscan is now part of the Biosynth Group. Twenty-five years later, the Pepscan methodology, evolved and modernized with the latest insights, is still an important part of Pepscan’s epitope mapping platform, which is instrumental in therapeutic antibody development.
If a benzodiazepine increases the frequency of channel opening by 300%, and a barbiturate increases the duration of their opening by 300%, then the combined effects of the drugs increases the channels' overall function by 900%, not 600%). The longest-acting barbiturates have half-lives of a day or more, and subsequently result in bioaccumulation of the drug in the system. The therapeutic and recreational effects of long-acting barbiturates wear off significantly faster than the drug can be eliminated, allowing the drug to reach toxic concentrations in the blood following repeated administration (even when taken at the therapeutic or prescribed dose) despite the user feeling little or no effects from the plasma-bound concentrations of the drug. Users who consume alcohol or other sedatives after the drug's effects have worn off, but before it has cleared the system, may experience a greatly exaggerated effect from the other sedatives which can be incapacitating or even fatal. Barbiturates induce a number of hepatic CYP enzymes (most notably CYP2C9, CYP2C19, and CYP3A4), leading to exaggerated effects from many prodrugs and decreased effects from drugs which are metabolized by these enzymes to inactive metabolites. This can result in fatal overdoses from drugs such as codeine, tramadol, and carisoprodol, which become considerably more potent after being metabolized by CYP enzymes.
=== 2025 elections === On October 5, 2024, Duterte announced that he will run for mayor of Davao City, with his son, incumbent Mayor Sebastian Duterte, as his running mate for vice mayor in 2025. He also rejected calls for him to run for senator, citing his old age. Duterte officially filed his candidacy on October 7; however, on November 7, he welcomed the candidacy of his former cabinet secretary, former Civil Service Commission chairperson Karlo Nograles as Davao City mayor, adding he is retired and wishes to give the position to the next generation. In May 2025, Duterte was elected as mayor despite his detention at The Hague by the ICC. However, he was unable to take his oath on the start of his term on June 30, 2025, due to his imprisonment. As a result, his son Sebastian, who was elected vice mayor, became acting mayor. On January 23, 2026, Sebastian was sworn in as mayor of Davao City, following his father's failure to take the oath of office within the six-month prescribed period due to his detention.
Cofran, Hurst & Hawks (2026) present a virtual reconstruction of the brain endocast of Homo naledi, providing evidence of presence of a combination of ancestral and derived features in the brain of the studied hominin. Madupe et al. (2026) determine the sex of at least 20 individuals of Homo naledi from the Rising Star cave system (Cradle of Humankind, South Africa) on the basis of proteomic analysis of tooth enamel, finding no evidence of male markers in the studied sample. Delagnes et al. (2026) study the mobility of Early Pleistocene hominins from the Lower Omo Valley (Shungura Formation, Ethiopia), providing evidence of transport of quartz for the production of Oldowan stone tools from the alluvial fans of the Hamar Range, over 10 km from the sites preserving the stone tools, located in areas that lacked stone material but had rich faunal assemblages. Evidence from the study of Oldowan tools from the Shungura Formation, indicating that different sediment types produced characteristic wear of the studied tools that can be distinguished wear caused by other types of sediment and from anthropogenic use-wear, is presented by Galland et al. (2026). Dominguez-Rodrigo et al.
Sources: en.wikipedia.org
This same proposal was proposed again in 1976, but further studies indicated that the recurrence rate was not better. In 1888, treatments were tried that entered the abdomen to make reattachments. Some did not agree with this and suggested an approach through the inguinal canal. In 1898, further abdominal approaches were proposed. No further advances have been noted until 1961 when reattachment of the anterior vaginal wall to Cooper's ligament began to be used. Unfortunately, posterior vaginal wall prolapse occurred in some patients even though the anterior repair was successful. In 1955, using mesh to support pelvic structures became common. In 1970, tissue from pigs began to be used to strengthen the anterior vaginal wall in surgery. Beginning in 1976, improvement in suturing began along with the surgical removal of the vagina being used to treat prolapse of the bladder. In 1991, assumptions about the detailed anatomy of the pelvic support structures began to be questioned regarding the existence of some pelvic structures and the non-existence of others. More recently, stem cells and robot-assisted laparoscopic surgery have been used to treat cystoceles.
Most antifreeze is made by mixing distilled water with additives and a base product, usually MEG (mono ethylene glycol) or MPG (mono propylene glycol). Ethylene glycol solutions first became available in 1926 and were marketed as "permanent antifreeze" since the higher boiling points provided advantages for summertime use as well as during cold weather. They are used today for a variety of applications, including automobiles, but there are lower-toxicity alternatives made with propylene glycol available. When ethylene glycol is used in a system, it may become oxidized to five organic acids (formic, oxalic, glycolic, glyoxalic and acetic acid). Inhibited ethylene glycol antifreeze mixes are available, with additives that buffer the pH and preserve alkalinity of the solution to prevent oxidation of ethylene glycol and formation of these acids. Nitrites, silicates, borates and azoles may also be used to prevent corrosive attack on metal. Ethylene glycol has a bitter, sweet taste and causes inebriation. The toxic effects of ingesting ethylene glycol occur because it is converted by the liver into 4 other chemicals that are much more toxic. The lethal dose of pure ethylene glycol is 1.4 ml/kg (3 US fluid ounces (90 ml) is lethal to a 140-pound (64 kg) person) but is much less lethal if treated within an hour. (see Ethylene glycol poisoning).
Eastern Cuba, and particularly Oriente Province, with its cultural epicentre at Santiago de Cuba, was for most of Cuba's history culturally distinct from Western Cuba and the city of Havana. Debates between Catholics, Protestants, and Secularists stirred further divisions. When the Cuban identity was being developed as distinct from a Spanish colony, hot debates between autonomists and separatists took place in the Cuban Masonic Lodges. The issue of slavery was hotly debated within all secret societies, not only in Cuba, but in the entire Caribbean and the Gulf of Mexico, and especially within the societies of Freemasonry in Latin America. Views on slavery would prove to quickly cause a strife between two very different brands of Freemasonry that developed in Cuba. The brand of Freemasonry that eventually won-over in Cuba was pro-independence and anti-slavery, conjoined with a prevailing current of Spanish liberal constitutionalism.
=== Argentina === In Argentina, the residency (Spanish, residencia) consists of a three to four years of practical and research activities in the field selected by both the candidate and already graduated medical practitioners. Specialized fields such as neurosurgery or cardio-thoracic surgery require longer training. Through these years, consisting of internships, social services, and occasional research, the resident is classified according to their residency year as an R1, R2, R3 or R4. After the last year, the "R3 or R4 Resident" obtains the specialty (especialidad) in the selected field of medicine.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.